AOR:LSE-Rua Life Sciences Plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 126.50

Change

0.00 (0.00)%

Market Cap

GBX 0.02B

Volume

0.06M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

AOR Stock Forecast & Price:
Based on the Rua Life Sciences Plc stock forecasts from 0 analysts, the average analyst target price for Rua Life Sciences Plc is not available over the next 12 months. Rua Life Sciences Plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Rua Life Sciences Plc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Rua Life Sciences Plc’s stock price was GBX 126.50. Rua Life Sciences Plc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Rua Life Sciences Plc
No recent average analyst rating found for Rua Life Sciences Plc

About Rua Life Sciences Plc (AOR:LSE)

Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in the United Kingdom. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable ...Read More

Company Website : http://www.rualifesciences.com

Address : 163 Bath Street, Glasgow, United Kingdom, G2 4SQ

Employees : 6

Fiscal Year End : March

Currency: GBX

Country : UK

Technical Indicators

Beta : 1.28

200 Day Moving Average : 107.67

50 Day Moving Average : 134.44

Shares Held By Insiders : 69.94%

Shares Held by Institutions : 20.41%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABC:LSE Abcam plc

+13.00 (+0.97%)

 GBX3.02B 220.00 66.30
ONT:LSE Oxford Nanopore Technologies L..

-1.00 (-0.42%)

 GBX2.03B N/A -12.14
GNS:LSE Genus PLC

-64.00 (-2.43%)

 GBX1.80B 44.03 21.91
PRTC:LSE PureTech Health plc

-2.00 (-0.93%)

 GBX0.62B 225.00 -40.45
ERGO:LSE Ergomed Plc

-12.00 (-1.04%)

 GBX0.57B 45.44 28.00
SLN:LSE Silence Therapeutics plc

N/A

 GBX0.48B N/A N/A
OXB:LSE Oxford BioMedica PLC

+5.00 (+1.35%)

 GBX0.36B 18.55 -695.86
AVCT:LSE Avacta Group PLC

+1.00 (+0.98%)

 GBX0.26B N/A -8.74
VRP:LSE Verona Pharma plc

N/A

 GBX0.23B N/A N/A
REDX:LSE Redx Pharma Plc

N/A

 GBX0.19B N/A -11.24

ETFs Containing AOR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 607.69% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 607.69% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 43.97% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.97% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 64.46% N/A N/A N/A N/A
Risk Adjusted Return 68.21% N/A N/A N/A N/A
Market Capitalization 0.02B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.78 N/A N/A N/A N/A
Price / Cash Flow Ratio -46.75 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -17.53% N/A N/A N/A N/A
Return on Invested Capital -35.68% N/A N/A N/A N/A
Return on Assets -12.71% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.28 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.